Newly discovered biologic agent used for psoriasis treatment

Psoriasis is an autoimmune inflammatory skin disorder that affects 2–3% of the world's population. It has distinct features, such as accelerated keratinocyte proliferation and proinflammatory cytokines secretion. Topical, systemic, phototherapy, and biologic therapies are used in the treatment. Topical therapies are preferred over systemic medicines for mild to moderate psoriasis. Systemic therapies are best for severe pathological conditions. Immunosuppressants, biological agents, and recently licensed phosphodiesterase-4 (PDE4) inhibitors are some of the systemic therapies. Present therapies have a lot of drawbacks, and new discoveries in the pathogenesis of psoriasis are opening the way for novel therapeutics that target the disease at the molecular level. Multiple small molecules, PDE-4 inhibitors, biologics, and immunomodulators, as well as newly discovered Janus kinases (JAK) inhibitors, were found to be effective. This article focuses on many emerging treatments as well as presently approved psoriasis medications.